-
2022-502193-16-00
5
2023-11-14
Chronic lymphocytic leukemia, Multiple Myeloma and Non-Hodgkin Lymphom
-
2023-503224-66-00
5
2023-10-31
Atrial Fibrillation
-
2022-501515-14-00
5
2023-09-29
Newly Diagnosed Multiple Myeloma (NDMM)
-
2023-510336-36-00
5
2023-05-05
Paroxysmal nocturnal hemoglobinuria (PNH)
-
2023-510548-19-00
4
2023-03-02
Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis
-
2023-510346-25-00
5
2022-09-01
Hypereosinophilic Syndrome (HES)
-
2023-507557-16-00
5
2022-08-31
chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
-
2022-502425-18-00
5
2022-04-19
Adenocarcinoma of the prostate
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)
-
2024-516291-16-00
3
2021-10-26
Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid
-
2024-515273-10-00
7
2021-10-19
Relapsed or refractory Multiple Myeloma (r/r MM)
-
2023-507372-42-00
4
2021-09-20
Schizophrenia
-
2023-509357-31-00
1
2021-06-01
Multiple Sclerosis (MS)
-
2023-503435-17-00
5
2021-03-31
Juvenile psoriatic arthritis
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2024-514010-12-00
1
2020-12-03
Advanced Malignancies
-
2023-509846-36-00
9
2020-05-29
Advanced Solid Tumors
-
2023-506914-32-00
4
2020-05-05
Pan tumor
-
2023-507149-27-00
5
2019-11-04
Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small
-
2023-508455-38-00
5
2019-09-12
Hyperkalaemia
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2025-523487-21-00
2
2026-05-05
cytomegalovirus (CMV) infection and/or disease that is refractory (wit
-
2025-523051-64-00
4
2026-01-26
Moderate to severe chronic plaque psoriasis